Q1 FY27Published 09 Jul 2026Call held 09 Jul 2026
DRREDDY Q1 FY27 Earnings Call Transcript & Analysis
Temporary delay in commercial supply of Semaglutide injection due to an impurity issue found during API scale-up.
Read full transcript & analysis
Earnings calls
Dr. Reddy's Laboratories Limited concall ledger
Every earnings call for DRREDDY — management tone, guidance, KPIs and promise tracking, quarter by quarter.
DRREDDY · 6 transcripts · Healthcare · latest Q1 FY27Dr. Reddy's Laboratories Limited has 6 earnings calls on record here, a Healthcare company, most recently Q1 FY27. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Q4 FY26Published 12 May 2026Call held 12 May 2026
DRREDDY Q4 FY26 Earnings Call Transcript & Analysis
Adjusted EBITDA₹8,419 crGross Margin48%
Adjusted EBITDA (FY26) ₹8,419 cr; Gross Margin (Q4) 48%. Full year adjusted EBITDA margin at ~25%, consistent with aspirations.
Read full transcript & analysisQ2 FY26Published 21 Jan 2026Call held 28 Oct 2025
DRREDDY Q2 FY26 Earnings Call Transcript & Analysis
Operating Revenue₹11,905 cr+29% YoYOperating EBITDA₹1,509 cr+40% YoYEBITDA Margin12.7 percent+100% YoYPAT₹906 cr+37% YoYPBT₹1,226 cr+37% YoY
Operating Revenue ₹11,905 cr (+29% YoY); Operating EBITDA ₹1,509 cr (+40% YoY); EBITDA Margin 12.7 percent (+100% YoY). Achieved highest ever quarterly sales in both ICE and EV segments with strong outperformance vs industry.
Read full transcript & analysisQ2 FY26Published 24 Oct 2025Call held 24 Oct 2025
DRREDDY Q2 FY26 Earnings Call Transcript & Analysis
Consolidated Revenue₹8,805 cr+10% YoYEBITDA₹2,351 cr+3% YoYEBITDA Margin26.7%−174% YoYProfit After Tax₹1,437 cr+14% YoY
Consolidated Revenue ₹8,805 cr (+10% YoY); EBITDA ₹2,351 cr (+3% YoY); EBITDA Margin 26.7% (−174% YoY). Revenue growth of 9.8% YoY to ₹8,805 crores with near double-digit growth.
Read full transcript & analysisQ1 FY26Published 23 Jul 2025Call held 23 Jul 2025
DRREDDY Q1 FY26 Earnings Call Transcript & Analysis
EBITDA₹2,278 cr+5% YoYEBITDA Margin26.7%−1% YoYProfit After Tax₹1,419 cr+2% YoY
EBITDA ₹2,278 cr (+5% YoY); EBITDA Margin 26.7% (−1% YoY); Profit After Tax ₹1,419 cr (+2% YoY). Consolidated revenues grew 11% YoY to ₹8,545 crores ($997 million).
Read full transcript & analysisQ4 FY25Published 09 May 2025Call held 09 May 2025
DRREDDY Q4 FY25 Earnings Call Transcript & Analysis
Q4 Revenue₹8,506 cr+20% YoYFull Year Revenue₹32,554 cr+17% YoYQ4 EBITDA₹2,475 cr+32% YoYFull Year EBITDA₹9,213 cr+11% YoYQ4 Gross Margin55.6 percentage−3% YoY
Q4 Revenue ₹8,506 cr (+20% YoY); Full Year Revenue ₹32,554 cr (+17% YoY); Q4 EBITDA ₹2,475 cr (+32% YoY). Record high revenues exceeding $3.8 billion for full year FY25.
Read full transcript & analysis